Cervical cancer is the fourth most common cancer in women around the world. The 5-year survival rate exceeds 90% at early ...

Working with the same tumor slices that pathologists use to diagnose and guide treatment of patients, however, Carstens can ...

Research reveals IL-12 nanoparticles paired with checkpoint inhibitors can eradicate ovarian tumors, showcasing potential for ...

Scientists found that nearly every cancer harbors its own distinct community of microbes – tiny passengers that can influence how tumors start, spread, and respond to treatment, paving the way for a ...

Nanoparticles carrying IL-12 are non-toxic, elicit strong systemic antitumor immunity, and sensitize ovarian tumors to ICI therapy, a new study shows.

Merck and Eisai announced termination of a phase III trial of pembrolizumab plus lenvatinib (Lenvima) and transarterial chemoembolization (TACE) for unresectable liver cancer after an interim analysis ...

Targeted particles carrying the cytokine IL-12 can jump-start T cells, allowing them to clear tumors while avoiding side ...

Cancer immunotherapy, which uses drugs that stimulate the body's immune cells to attack tumors, is a promising approach to ...

The annual event will be held Saturday, Nov. 8 from 8 a.m. - 12 p.m. at Cranes Roost Park in Altamonte Springs.

The U.S. Food and Drug Administration (FDA) has granted fast track designation to the antibody-drug conjugate JSKN003 for the ...